Targeting Gut Microbiome With Prebiotic in Patients With CKD: The TarGut-CKD Study.

ABSTRACT:

Introduction

Disruption of gut microbiota underpins some of the metabolic alterations observed in chronic kidney disease (CKD).

Methods

In a nonrandomized, open-label, 3-phase pilot trial, with repeated measures within each phase, we examined the efficacy of oligofructose-enriched inulin (p-inulin) in changing the gut microbiome and their metabolic products in 15 patients with CKD. The stability of microbiome and metabolome was studied during the pretreatment phase (8 weeks), a p-inulin treatment phase (12 weeks), and a post treatment phase (8 weeks) of the study.

Results

Study participants completed 373 of the 420 expected study visits (88.8%). Adherence to p-inulin was 83.4%. 16S rRNA sequencing was performed in 368 stool samples. A total of 1085 stool, urine, and p

SUBMITTER: Sohn MB 

PROVIDER: S-EPMC10927482 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature